Release Date: 13 July 2024
In late April 2024, ImmunityBio unveiled a groundbreaking advancement in the field of oncology with the FDA’s approval of Anktiva plus Bacillus Calmette-Guandeacute;rin (BCG) for the treatment of patients grappling ...
Release Date: 12 July 2024
As Pfizer’s latest milestone in biopharmaceutical innovation, Elrexfio stands as the newest approved bispecific antibody for multiple myeloma patients. Designed as a T cell engager, it targets BCMA on malignant cell...
Release Date: 12 July 2024
The US maintains a commanding presence in the bispecific antibodies market, witnessing robust sales growth. From USD 3.65 Billion in 2022, sales surged to USD 5.82 Billion in 2023, marking a remarkable increase of 59.45%....
Release Date: 12 July 2024
The US emerges as a global leader in bispecific antibody research, development, and approval, underscoring its pivotal role in advancing this therapeutic class. With eleven out of twelve globally approved bispecific antib...
Release Date: 12 July 2024
Bispecific T cell engagers represent a revolutionary class of therapeutics, with eight out of twelve bispecific antibodies harnessing their power. Bispecific T cell engagers function by simultaneously binding to T cells a...
Release Date: 12 July 2024
Sales of bispecific antibodies surged to USD 8.70 Billion in 2023, marking a remarkable 51.04% increase from the previous year’s USD 5.76 Billion. Moreover, in the first quarter of 2024, the market was valued at aro...
Release Date: 12 July 2024
Regulatory designations have played a crucial role in shaping the landscape of the bispecific antibodies market, offering streamlined pathways for development and expedited approval processed. Designations such as Breakth...
Release Date: 12 July 2024
Bispecific antibodies exert their therapeutic effects through intricate mechanisms of action. By engaging two distinct targets, they can bridge immune cells to tumors, such as T cells to cancer cells, facilitating tumor c...
Release Date: 12 July 2024
Roche emerges as a dominant force in the bispecific antibodies market, with three pioneering therapies that have reshaped treatment paradigms across various conditions. Hemlibra’s breakthrough in hemophilia manageme...
Release Date: 12 July 2024
JNJ asserts in dominance in the bispecific antibodies market with a portfolio of groundbreaking therapies, spearheaded by Rybrevant for NSCLC, and Tecvayli and Talvey for multiple myeloma. These first-in-class treatments ...
Release Date: 12 July 2024
Bispecific antibodies hold significant promise for the treatment of viral infections, leveraging their unique dual-targeting capabilities to combat viral infections. By simultaneously binding to viral antigens and immune ...
Release Date: 12 July 2024
Non-Hodgkin lymphoma stands out as a prominent indication with numerous bispecific antibodies approved, particularly those targeting CD20, an essential antigen in lymphoma pathogenesis. Approved for follicular lymphoma, l...
Release Date: 12 July 2024
Multiple myeloma emerges as a leading indication for bispecific antibodies, with approved therapies targeting BCMA and GPRC5D, two key antigens in disease pathogenesis. Clinical trials further underscore the significance ...
Release Date: 12 July 2024
Bispecific antibodies have emerged as a transformative therapeutic option for hematological malignancies, with seven out of twelve approved bispecific antibodies indicated for leukemia, lymphoma and multiple myeloma. Thes...
Release Date: 12 July 2024
Cancer dominates the scene of approved bispecific antibodies and ongoing clinical studies because of the pressing unmet medical needs and therapeutic potential of these innovative agents. Bispecific antibodies provide a n...